Navigation Links
SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models
Date:6/13/2008

DUBLIN, Calif., June 13 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark, that its lead, oral PIM kinase inhibitor, SGI-1776, causes tumor regression in acute myologenous leukemia (AML) xenograft models (abstract #744).

In a poster presentation entitled "A potent small molecule PIM kinase inhibitor with in vivo oral availability and activity in cell lines from hematological malignancies," Dr. Gregory Berk, SuperGen's Chief Medical Officer, detailed how scientists used SuperGen's CLIMB(TM) technology to build a model that allowed for the creation of small molecule PIM kinase inhibitors. SGI-1776 was identified as an orally available, potent and selective inhibitor of the PIM kinases. SGI-1776 induces cell cycle arrest, dose dependent apoptosis and a reduction in phospho-BAD levels in leukemia and lymphoma cell lines. Phospho-BAD is a direct substrate for PIM, and may serve as a useful in vivo biomarker for future clinical trials. Most notably, SGI-1776 induced significant tumor regression in MOLM-13 and MV-4-11 (AML) xenograft models.

"Our PIM kinase inhibitor, SGI-1776, has the potential to be an effective treatment for AML and other malignancies that over-express PIM kinase," said Dr. James Manuso, SuperGen's President and Chief Executive Officer. "The data also provide support for the use of our CLIMB(TM) technology to identify and rapidly advance candidates into the clinic. We plan to initiate Phase 1 clinical trials with SGI-1776 in solid tumors and leukemias later this year. SGI-1776 may become the first drug in this class of inhibitors to enter the clinic."

SuperGen's schedule of presentations at EHA is as follows:

Date Time (PDT) Abstract # and Title

Friday, June 13 8:45 a.m.-10 a.m. #744 - A potent small molecule PIM

kinase inhibitor with in vivo oral

availability and activity in cell

lines from hematological

malignancies

Sunday, June 15 1:30 a.m.-2:45 a.m. #741 - SGI-1252: A potent small

Oral Presentation molecule JAK2 inhibitor

Hall C5

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts

Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications Manager, Investor Relations

& Business Development Tel: (925) 560-2845

Tel: (925) 560-0100 E-mail: mary.vegh@supergen.com

E-mail: tenns@supergen.com


'/>"/>
SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
3. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
4. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
5. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
6. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
9. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
10. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
11. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... Florida , February 9, 2016 ... today announced a collaboration with 10x Genomics to ... (NGS), single-cell biology and bioinformatics. --> ... a collaboration with 10x Genomics to develop and ... biology and bioinformatics. --> QIAGEN N.V. ...
(Date:2/9/2016)... , Feb. 9, 2016 Mast Therapeutics, ... clinical-stage therapies for sickle cell disease and heart failure, today ... and warrants to purchase common stock in an underwritten public ... and there can be no assurance as to whether or ... actual size or terms of the offering.   ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 10, 2016 , ... Everseat has joined the award-winning Allscripts ... physicians. The integration will enable Allscripts users to post open appointments to the ... app. , The partnership gives Everseat substantial added power to help Allscripts meet ...
(Date:2/10/2016)... ... 10, 2016 , ... Workrite Ergonomics this week announced the launch of the ... , “Our goal was to develop a product from the ground up that ... ever created.” said Darren Hulsey, Product Manager for Workrite Ergonomics. “The Conform series ...
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans over steep cost increases ... D a decade ago, according to The Senior Citizens League (TSCL). ... are coping with rapidly rising costs. “The implications are chilling, particularly for people ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... Body Specialists are delighted to welcome a new addition to their growing practice. ... Body Specialists as a nurse practitioner performing cosmetic procedures including injectables, ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... It’s that ... Traci Davis, the new president of the Interscholastic Athletic Association of Maryland (IAAM), Hall ... well how quickly fitness goals are cast aside. , That’s why one of her ...
Breaking Medicine News(10 mins):